Article

De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression

2023-07-15

Abstract excerpt

p16 is a tumor suppressor encoded by the CDKN2A gene whose expression is lost in ∼50% of all human cancers. In its canonical role, p16 inhibits the G1-S phase cell cycle progression through suppression of cyclin dependent kinases. Interestingly, p16 also has roles in metabolic reprogramming, and we previously published that loss of p16 promotes nucleotide synthesis via the pentose phosphate pathway. Whether other...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b72221cb-fccf-5e5f-bbe9-e976313ac6d1
DOI: 10.1101/2023.07.15.549149

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expressionDOI 10.1101/2023.07.15.549149Read

De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 ExpressionSemantic proximity Read

Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic ReprogrammingSemantic proximity Read

BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.Semantic proximity Read

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.Semantic proximity Read

Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategySemantic proximity Read

Targeting polyamine metabolism and function in cancer and other hyperproliferative diseasesSemantic proximity Read

Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance roleSemantic proximity Read

Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTsSemantic proximity Read

Collateral damage of NUDT15 deficiency in cancer provides a cancer pharmacogenetic therapeutic window with thiopurinesSemantic proximity Read

Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.Semantic proximity Read

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA RepairSemantic proximity Read

Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline gliomaSemantic proximity Read